CMND
Clearmind Medicine Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.16
−31.76%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -18.0%
- EBIT
- -14.7%
- EPS
- +74.7%
- Free cash flow
- -4.9%
- Operating cash flow
- -4.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +22.4%
- EBIT
- +1.4%
- Net income
- +26.6%
- EPS
- +55.3%
- Free cash flow
- +30.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026